Vetoryl capsules contain the drug trilostane which has demonstrated to be effective in the treatment of Cushings syndrome in dogs. Vetoryl will be indicated for use in pituitary-dependent hyperadrenocorticism which comprises the majority of cases of Cushing's syndrome in dogs. Also Vetoryl has received designation status as a Minor Use drug treatment of hyperadrenocorticism caused by adrenal tumors - the first drug to receive an approval for this indication and the first drug to receive a Minor Drug Use designation in dogs.